WHO preferred product characteristics for next generation influenza vaccines, second edition

Overview

In 2017, WHO published Preferred Product Characteristics (PPCs) to guide the development of next-generation influenza vaccines, and to encourage innovation and address global public health needs. While developed for global use, it is highly desirable for next-generation influenza vaccines to be particularly suitable and available for use in low- and middle-income countries (LMICs). The PPCs also provide early guidance for vaccine development, considering factors such as safety, efficacy, programmatic suitability and access.

This document, a revised version to the first edition of the PPC, reflects advancements in influenza vaccine research, updated WHO guidance, and lessons learned from the COVID-19 pandemic. This second edition PPC focus on developing safe, more efficacious influenza vaccines that offer greater breadth and prolonged protection beyond a single influenza season and are suitable for programmatic use in LMICs.